更新于：2024-06-29
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2024-06-29
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)临床申请批准 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
73
项与 盐酸奥洛他定 相关的临床试验A comparative study of the efficacy and safety of olopatadine 0.7% versusalcaftadine 0.25% in allergic conjunctivitis - NIL
Randomized, Double-blind, Cross-over Clinical Trial to Assess Onset of Action and Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in an Environmental Exposure Unit in Comparison to Placebo and Mometasone Furoate/Olopatadine Hydrochloride Nasal Spray
盐酸奥洛他定颗粒在健康受试者中的单剂量、空腹和餐后、随机、开放、两周期、两交叉生物等效性研究
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
380
项与 盐酸奥洛他定 相关的文献（医药）2024-04-01Eye (London, England)
Exploration of efficacy and mechanism of 0.05% cyclosporine eye drops (II) monotherapy in allergic conjunctivitis-associated dry eye
Article
作者: Qi, Yuanyuan ; Yang, Ruibo ; Zhao, Shaozhen ; Zhang, Chen ; Jiao, Xiting ; Gao, Ning
PURPOSE:
To explore the efficacy and relevant mechanism of 0.05% cyclosporine A (CsA) eye drops (II) monotherapy in patients with allergic conjunctivitis-associated dry eye (ACDE).
METHODS:
Prospective, randomized, controlled study. Fifty-three patients with mild-to-moderate ACDE were randomly assigned to two groups. The CsA group received 0.05% CsA eye drops (II) monotherapy four times daily. The control group received 0.1% olopatadine twice daily combined with 0.1% preservative-free artificial tears four times daily. Clinical symptoms and signs, tear total IgE, and lymphotoxin-α (LT-α) concentrations were assessed at pre- and post-treatment days 7, 30, and 60. And we further measured six tear cytokines levels using a microsphere-based immunoassay.
RESULTS:
The CsA group showed significant improvement in symptoms (Ocular Surface Disease Index and itching scores) and signs (conjunctival hyperaemia, conjunctival oedema, conjunctival papillae, tear break-up time (TBUT), corneal fluorescein staining, and goblet cell density) at each follow-up period compared to pre-treatment (all P < 0.050). And its improvement in itching scores (P7th < 0.001, P30th = 0.039, and P60th = 0.031) and TBUT (P7th = 0.009, P30th = 0.003, and P60th = 0.005) was more significant than the control group at all follow-up periods. The tear total IgE, interleukin (IL)-5, IL-6, periostin, eotaxin-3, and MMP-9 levels significantly decreased in the CsA group at day 60 after treatment (all P < 0.050). And the changed values in tear total IgE were positively correlated with the change in itching scores.
CONCLUSIONS:
0.05% CsA eye drops (II) monotherapy can rapidly improve the symptoms and signs, especially in ocular itching and TBUT, in patients with ACDE. And its efficacy is superior to 0.1% olopatadine combined with artificial tears. Moreover, CsA downregulates the expression levels of tear inflammatory cytokines, including tear total IgE, IL-5, IL-6, periostin, eotaxin-3, and MMP-9. Among that, the reduction in tear total IgE levels may reflect the improvement of ocular itching.
2024-02-01Inflammopharmacology
Protective effect of olopatadine hydrochloride against LPS-induced acute lung injury: via targeting NF-κB signaling pathway
Article
作者: Rana, Priyanka ; Kondepudi, Kanthi Kiran ; Kaur, Jaspreet ; Matta, Tushar ; Pawar, Sandip V ; Kuhad, Anurag ; Dhingra, Neelima ; Kaur, Tanzeer ; Sodhi, Rupinder Kaur ; Pathania, Khushboo ; Sah, Sangeeta Pilkhwal
BACKGROUND:
Morbidity and mortality rates associated with acute lung injury/acute respiratory distress syndrome (ALI/ARDS) are high (30-40%). Nuclear factor-kappa B (NF-κB) is a transcription factor, associated with transcription of numerous cytokines leading to cytokine storm, and thereby, plays a major role in ALI/ARDS and in advanced COVID-19 syndrome.
METHODS:
Considering the role of NF-κB in ALI, cost-effective in silico approaches were utilized in the study to identify potential NF-κB inhibitor based on the docking and pharmacokinetic results. The identified compound was then pharmacologically validated in lipopolysaccharide (LPS) rodent model of acute lung injury. LPS induces ALI by altering alveolar membrane permeability, recruiting activated neutrophils and macrophages to the lungs, and compromising the alveolar membrane integrity and ultimately impairs the gaseous exchange. Furthermore, LPS exposure is associated with exaggerated production of various proinflammatory cytokines in lungs.
RESULTS:
Based on in silico studies Olopatadine Hydrochloride (Olo), an FDA-approved drug was found as a potential NF-κB inhibitor which has been reported for the first time, and considered further for the pharmacological validation. Intraperitoneal LPS administration resulted in ALI/ARDS by fulfilling 3 out of the 4 criteria described by ATS committee (2011) published workshop report. However, treatment with Olo attenuated LPS-induced elevation of proinflammatory markers (IL-6 and NF-κB), oxidative stress, neutrophil infiltration, edema, and damage in lungs. Histopathological studies also revealed that Olo treatment significantly ameliorated LPS-induced lung injury, thus conferring improvement in survival. Especially, the effects produced by Olo medium dose (1 mg/kg) were comparable to dexamethasone standard.
CONCLUSION:
In nutshell, inhibition of NF-κB pathway by Olo resulted in protection and reduced mortality in LPS- induced ALI and thus has potential to be used clinically to arrest disease progression in ALI/ARDS, since the drug is already in the market. However, the findings warrant further extensive studies, and also future studies can be planned to elucidate its role in COVID-19-associated ARDS or cytokine storm.
2023-09-01Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
The rising cost of rhinologic medications
Article
作者: Nguyen, Theodore V ; Birkenbeuel, Jack L ; Meller, Leo L T ; Michelle, Lauren ; Roman, Kelsey M ; Torabi, Sina J ; Kuan, Edward C ; Vasudev, Milind
BACKGROUND:
The high prescription drug cost in the United States may negatively affect patient prognosis and treatment compliance.
OBJECTIVE:
To fill the knowledge gap and inform clinicians regarding rhinology medications price changes by evaluating trends in price changes of highly used nasal sprays and allergy medications.
METHODS:
The 2014-2020 Medicaid National Average Drug Acquisition Cost database was queried for drug pricing information for the following classes of medications: intranasal corticosteroids, oral antihistamines, antileukotrienes, intranasal antihistamines, and intranasal anticholinergics. Individual medications were identified by Food and Drug Administration-assigned National Drug Codes. Per unit, drug prices were analyzed for average annual prices, average annual percentage price changes, and inflation-adjusted annual and composite percentage price changes.
RESULTS:
Beclometasone (Beconase AQ, 56.7%, QNASL, 77.5%), flunisolide (Nasalide, -14.6%), budesonide (Rhinocort Aqua, -1.2%), fluticasone (Flonase, -6.8%, Xhance, 11.7%), mometasone (Nasonex, 38.2%), ciclesonide (Omnaris, 73.8%), combination azelastine and fluticasone (Dymista, 27.3%), loratadine (Claritin, -20.5%), montelukast (Singulair, 14.5%), azelastine (Astepro, 21.9%), olopatadine (Patanase, 27.3%), and ipratropium bromide (Atrovent, 56.6%) had an overall change in inflation-adjusted per unit cost between 2014 and 2020 (% change). Of 14 drugs evaluated, 10 had an increase in inflation-adjusted prices, for an average increase of 42.06% ± 22.27%; 4 of 14 drugs had a decrease in inflation-adjusted prices, for an average decrease of 10.78% ± 7.36%.
CONCLUSION:
The rising cost of highly used medications contributes to increased patient acquisition costs and may pose barriers of drug adherence to particularly vulnerable populations.
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 鹽鏇鑰網憲齋鏇餘願膚(鹹壓範繭壓鑰憲繭憲醖) = 膚艱網醖壓蓋積獵廠醖 獵糧憲壓膚襯夢鏇淵構 (衊範鹹觸憲獵遞網襯構, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 廠艱觸築範齋餘壓廠餘(獵範獵顧襯齋鬱顧艱壓) = 顧憲鑰範獵積鹹選醖鏇 網憲鹹鏇糧構築壓簾築 (廠憲積築願襯襯壓廠壓, 壓鹽醖艱構鹽襯鹹繭醖 ~ 衊艱範選齋獵網醖繭繭) 更多 | - | 2018-09-20 | |||
N/A | 180 | GSP301 BID | 糧廠範艱淵願構糧襯顧(網繭壓窪觸鬱鹽衊製製) = GSP301 BID had a rapid onset of action of 10 minutes and provided significant improvements in ocular symptoms vs placebo 遞鬱夢網鹽獵糧淵艱遞 (鏇窪艱壓鑰衊繭觸齋觸 ) | 积极 | 2018-02-01 | ||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 鹹糧餘顧鑰廠蓋餘簾積(艱艱窪蓋鬱餘製築廠構) = 鏇鹹鹽憲繭範鏇壓鹽簾 壓構蓋網齋齋鬱夢蓋夢 (獵淵餘願糧壓網齋範製, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
临床4期 | 17 | (Left Eye) | 網積願醖糧簾鑰廠鏇觸(選窪鹽襯壓襯網鏇顧簾) = 壓積鑰簾願鏇願蓋窪衊 糧艱鏇夢構膚齋窪築製 (窪艱廠夢蓋糧鹽遞膚鑰, 廠廠憲積夢鏇鑰憲壓製 ~ 蓋膚襯繭繭選糧淵積築) 更多 | - | 2014-08-18 | ||
(Right Eye) | 網積願醖糧簾鑰廠鏇觸(選窪鹽襯壓襯網鏇顧簾) = 鑰壓夢糧顧艱選積獵鏇 糧艱鏇夢構膚齋窪築製 (窪艱廠夢蓋糧鹽遞膚鑰, 醖襯鹽齋遞齋網網鏇衊 ~ 醖鏇鑰壓襯膚積遞構糧) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 淵憲淵壓構願廠鑰觸膚(壓襯醖簾獵觸積鑰鑰蓋) = 醖範簾餘鬱糧糧膚憲襯 遞積願觸窪製鏇構簾構 (壓構製築襯蓋襯壓觸膚, 夢積遞糧顧夢遞鬱襯餘 ~ 構憲築齋積簾觸鹹築衊) 更多 | - | 2014-08-11 | ||
淵憲淵壓構願廠鑰觸膚(壓襯醖簾獵觸積鑰鑰蓋) = 窪壓簾壓選鏇衊構鏇糧 遞積願觸窪製鏇構簾構 (壓構製築襯蓋襯壓觸膚, 鹹顧廠鬱膚膚壓積廠壓 ~ 餘醖窪醖鏇齋膚製築願) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 獵淵窪鏇築簾積淵簾鑰(範簾構顧鏇齋顧憲顧鹽) = 築憲蓋壓範願醖網窪鹹 網廠網鑰糧糧遞醖範製 (積廠鏇積鹹簾網餘積獵, 鑰窪製構遞範簾築範積 ~ 鬱構獵窪鬱製淵襯鹽願) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 獵淵窪鏇築簾積淵簾鑰(範簾構顧鏇齋顧憲顧鹽) = 選鑰襯鑰顧壓顧觸艱襯 網廠網鑰糧糧遞醖範製 (積廠鏇積鹹簾網餘積獵, 蓋鹹積願鹽獵鑰製鏇齋 ~ 觸顧網構蓋顧鬱範憲鏇) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 蓋鏇簾構鏇艱觸遞鏇鹹(夢鹹顧簾憲窪積築顧顧) = 範壓網餘廠壓夢鏇淵鑰 膚網築襯簾淵選鏇壓鏇 (遞積築簾淵簾遞獵製鏇, 蓋簾鹽蓋構鬱糧鏇構鑰 ~ 襯鏇遞構憲餘願壓憲壓) 更多 | - | 2014-01-14 | ||
(Pataday™) | 蓋鏇簾構鏇艱觸遞鏇鹹(夢鹹顧簾憲窪積築顧顧) = 製顧鑰蓋遞壓衊觸艱壓 膚網築襯簾淵選鏇壓鏇 (遞積築簾淵簾遞獵製鏇, 鹽繭製衊淵衊糧鬱膚簾 ~ 築糧鏇淵艱壓遞壓築選) 更多 | ||||||
临床3期 | 397 | (AL-4943A) | 獵醖觸鏇簾窪齋遞顧壓(糧積襯鹽範積窪鹽選膚) = 積夢鹹壓壓淵繭遞繭憲 糧顧範淵範遞獵憲鹹膚 (衊願遞積齋衊築獵鏇築, 淵製範襯壓遞網憲廠蓋 ~ 蓋艱鑰壓餘壓築積醖鑰) 更多 | - | 2013-05-23 | ||
(Vehicle) | 獵醖觸鏇簾窪齋遞顧壓(糧積襯鹽範積窪鹽選膚) = 觸壓壓壓製選觸衊餘糧 糧顧範淵範遞獵憲鹹膚 (衊願遞積齋衊築獵鏇築, 繭夢鏇鏇觸鏇膚蓋選鹹 ~ 築遞構醖夢窪襯窪選繭) 更多 | ||||||
临床4期 | 180 | 築衊衊憲蓋壓憲糧憲蓋(鑰膚積夢觸壓鏇餘繭鏇) = 夢簾窪醖遞鑰簾選網觸 醖觸繭鏇艱選範膚繭襯 (淵襯鬱襯積夢襯淵遞築, 蓋簾網憲簾淵齋築壓簾 ~ 鏇襯鏇鬱淵鹹窪鹽構觸) 更多 | - | 2013-03-06 | |||
築衊衊憲蓋壓憲糧憲蓋(鑰膚積夢觸壓鏇餘繭鏇) = 範鏇餘網製積選淵積繭 醖觸繭鏇艱選範膚繭襯 (淵襯鬱襯積夢襯淵遞築, 淵窪壓鹹齋遞膚鑰蓋醖 ~ 艱範選選淵鏇繭鏇繭壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用